Dianthus Therapeutics (DNTH) Cash & Current Investments (2017 - 2025)

Dianthus Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $403.5 million for Q4 2025.

• On a quarterly basis, Cash & Current Investments rose 47.03% year-over-year to $403.5 million in Q4 2025; TTM through Dec 2025 was $403.5 million, a 47.03% increase from a year earlier, with the FY2025 full-year figure at $403.5 million, up 47.03% from the prior year.
• Cash & Current Investments held at $403.5 million in Q4 2025 per DNTH's latest filing, from $401.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $403.5 million in Q4 2025 and bottomed at $25.0 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $191.2 million (2021), against an average of $212.5 million.
• Across the five-year window, Cash & Current Investments tumbled 84.04% in 2023 and soared 1408.63% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $176.9 million in 2021, then slumped by 57.33% to $75.5 million in 2022, then surged by 130.12% to $173.7 million in 2023, then jumped by 57.95% to $274.4 million in 2024, then soared by 47.03% to $403.5 million in 2025.
• Per Business Quant, the three latest DNTH Cash & Current Investments figures stand at $403.5 million (Q4 2025), $401.6 million (Q3 2025), and $257.4 million (Q2 2025).